STOCK TITAN

Halozyme Therapeutics (HALO) Net Income by Year

HALO NASDAQ

Halozyme Therapeutics, Inc. reported $316.9M in net income in fiscal year 2025. This represents a decrease of 28.6% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to $413.6M in net income. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Halozyme Therapeutics, Inc. has filed alongside them.

FY2025 annual
Net Income $316.9M
YoY -28.6%
5Y CAGR +19.7%
10Y CAGR n/m
Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

HALO Net Income by Fiscal Year

Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricTTMFY2510-KFY2410-KFY2310-KFY2210-KFY2110-KFY2010-KFY1910-KFY1810-KFY1710-KFY1610-KFY1510-KFY1410-KFY1310-KFY1210-KFY1110-K
Net Income$413.6M$316.9M-28.6%$444.1M+57.7%$281.6M+39.3%$202.1M-49.8%$402.7M+212.0%$129.1Mn/m-$72.2Mn/m-$80.3M-227.6%$63.0Mn/m-$103.0Mn/m-$32.2Mn/m-$68.4Mn/m-$83.5Mn/m-$53.6Mn/m-$19.8M

TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

HALO Net Income by Quarter

Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.

MetricQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-KQ3'2410-QQ2'2410-QQ1'2410-QQ4'2310-KQ3'2310-Q
Net Income$229.9M+39.2%$150.0M+27.1%-$141.6M-203.3%$175.2M+27.9%$165.2M+77.1%$118.1M+53.7%$137.0M+60.5%$137.0M+67.4%$93.2M+24.7%$76.8M+93.9%$85.4M+48.0%$81.8M+32.8%

What net income means

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.

More Halozyme Therapeutics, Inc. financials

Frequently Asked Questions

What was Halozyme Therapeutics, Inc.'s net income in fiscal year 2025?

Halozyme Therapeutics, Inc. reported $316.9M in net income in fiscal year 2025.

How fast is Halozyme Therapeutics, Inc.'s net income growing?

Halozyme Therapeutics, Inc. (HALO) net income fell by 28.6% year over year, from $444.1M to $316.9M in fiscal year 2025.

What is Halozyme Therapeutics, Inc.'s net income over the last twelve months?

Halozyme Therapeutics, Inc. (HALO) reported $413.6M in net income over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.

Across the 15 fiscal years this page covers, Halozyme Therapeutics, Inc. (HALO) net income went from -$19.8M in fiscal year 2011 to $316.9M in fiscal year 2025.

Halozyme Therapeutics, Inc. (HALO) reported $229.9M in net income in Q2 2026. This represents an increase of 39.2% from the same quarter a year earlier.

Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Halozyme Therapeutics, Inc. (HALO) reported on that line in every period on record.